Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction

Background: Omentin-1 is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. Plasma levels of omentin-1 are decreased in obesity and other insulin-resistant states. Insulin resistance contributes to the changes of cholesterol synthesis and absorption as well. The aim o...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition & diabetes 2015-11, Vol.5 (11), p.e183-e183
Main Authors: Lesná, J, Tichá, A, Hyšpler, R, Musil, F, Bláha, V, Sobotka, L, Zadák, Z, Šmahelová, A
Format: Article
Language:English
Subjects:
692/699/2743/137/1418
692/699/2743/393
82/51
Clinical Nutrition
Diabetes
Epidemiology
Internal Medicine
Medicine
Medicine & Public Health
Metabolic Diseases
Original
original-article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Omentin-1 is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. Plasma levels of omentin-1 are decreased in obesity and other insulin-resistant states. Insulin resistance contributes to the changes of cholesterol synthesis and absorption as well. The aim of this study was to characterise omentin-1 plasma levels in obese patients with diabetes mellitus type 1 during weight reduction, and to elucidate the relationship between cholesterol metabolism and omentin-1. Methods: Plasma levels of omentin-1 were measured in obese type 1 diabetics ( n =14, body mass index >30 kg m −2 , age 29–62 years) by enzyme-linked immunosorbent assay (BioVendor). Gas chromatography with flame ionisation detector (Fisons Plc.,) was used to measure squalene and non-cholesterol sterols—markers of cholesterol synthesis and absorption (phase I). Measurements were repeated after 1 month (phase II; 1 week of fasting in the hospital setting and 3 weeks on a diet containing 150 g saccharides per day) and after 1 year (phase III) on a diet with 225 g saccharides per day. Results: Omentin-1 plasma levels were stable during phases I and II, but significantly increased ( P
ISSN:2044-4052
2044-4052
DOI:10.1038/nutd.2015.33